AbCellera Biologics (ABCL) Interest Coverage Ratio (2020 - 2026)

AbCellera Biologics (ABCL) posted Interest Coverage Ratio of 15.6 for Q1 2026, down 2970.01% on a QoQ basis from 0.51 in Q4 2025.

AbCellera Biologics (ABCL) Interest Coverage Ratio (2020 - 2026) Analysis & Trends

AbCellera Biologics' Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 15.6 for Q1 2026.

Quarterly Interest Coverage Ratio changed N/A year-over-year to 15.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 57.51 (changed N/A YoY) and the FY2025 annual result came in at 3.86, up 38.78% from the prior year.
Interest Coverage Ratio was 15.6 for Q1 2026 at AbCellera Biologics, down from 0.51 in the prior quarter.
Across five years, Interest Coverage Ratio topped out at 55.67 in Q1 2022 and bottomed at 17.73 in Q4 2023.
A 5-year average of 1.42 and a median of 2.82 in 2022 frame the typical range for Interest Coverage Ratio.
Annual changes were most pronounced in 2022 — Interest Coverage Ratio soared 224.17% — and 2023, when it plunged 529.49%.
AbCellera Biologics' Interest Coverage Ratio stood at 2.82 in 2022, then plunged by 529.49% to 17.73 in 2023, then surged by 91.78% to 1.46 in 2024, then jumped by 65.13% to 0.51 in 2025, then sank by 2970.01% to 15.6 in 2026.
Business Quant data shows ABCL's Interest Coverage Ratio at 15.6 in Q1 2026, 0.51 in Q4 2025, and 1.46 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	658.42
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.60
4	NuCana	279.75 Bn	279.75 Bn	-	-0.22
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.71
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	22.72
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-0.38
10	AbCellera Biologics	1.72 Bn	1.72 Bn	-	-15.60

Download Data